Working Toward a World Without Myeloma

Following several years in academia where I was focused on research and care of patients with multiple myeloma, I joined Janssen’s Oncology R&D team focused on hematologic malignancies to continue my interest from an exciting new vantage -- developing innovative treatments for multiple myeloma.

I was drawn to Janssen for its innovative focus and commitment to multiple myeloma, along with an unwavering mindset of putting patients first. These tenets resonate deeply with me having cared for brave women and men facing a diagnosis of multiple myeloma, and always wanting and hoping to do more for them and their families.

Today, we are using all tools available, including deeper understanding of disease biology and advanced data science to develop new therapeutics that can achieve deeper and more durable remissions in our mission towards a cure. We are also developing treatments for patients at high-risk of developing myeloma with a focus to intercept and, ultimately, prevent the occurrence of this deadly disease.

I believe we are on a path to truly transform the treatment of multiple myeloma through exciting new therapeutic approaches on the horizon. In my view, a world without myeloma may not be too far off.

Like so many of us, and for me, cancer is a personal journey. Dear family members and friends have been impacted by this disease. Throughout September -- Blood Cancer Awareness Month -- please join me and Janssen in supporting the millions of courageous patients around the world recently diagnosed or battling a form of blood cancer. It’s these individuals who inspire us each and every day to do all that we can in our mission to eradicate cancer.